Involvement of Nervous System Pathways in Primary Sjögren's Syndrome

Rheumatic Disease Clinics of North America

Volumn 34, Issue 4, 2008, Pages 885-906

  Segal, Barbara ^a   Carpenter, Adam ^a   Walk, David ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Neurologic disorders; Sj gren's syndrome

Indexed keywords

ALPHA INTERFERON; AQUAPORIN; AUTOANTIBODY; AZATHIOPRINE; BETA INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DULOXETINE; EPRATUZUMAB; EXTRACTABLE NUCLEAR ANTIGEN ANTIBODY; GABAPENTIN; GLATIRAMER; IMMUNOGLOBULIN; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 1; INTERLEUKIN 6; LIDOCAINE; LOCAL ANESTHETIC AGENT; METHYLPREDNISOLONE; MUSCARINIC M3 RECEPTOR; NARCOTIC ANALGESIC AGENT; NATALIZUMAB; PHOSPHOLIPID ANTIBODY; PREGABALIN; RITUXIMAB; RO ANTIBODY; STEROID; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VENLAFAXINE;

ANXIETY; AUTOIMMUNITY; AUTONOMIC NEUROPATHY; BRAIN ANGIOGRAPHY; BRAIN BIOPSY; BRAIN VASCULITIS; CELLULAR IMMUNITY; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL FEATURE; CLINICAL TRIAL; CRANIAL NEUROPATHY; CRYOGLOBULINEMIA; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DRUG MEGADOSE; GUILLAIN BARRE SYNDROME; HUMAN; MONONEUROPATHY MULTIPLEX; MULTIPLE SCLEROSIS; MYELITIS; MYELOOPTIC NEUROPATHY; NECROTIZING ARTERITIS; NERVE BIOPSY; NEUROLOGIC DISEASE; NEUROPATHIC PAIN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; SENSORIMOTOR NEUROPATHY; SENSORY NEUROPATHY; SJOEGREN SYNDROME; SKIN BIOPSY; SPINAL CORD DISEASE; VASCULAR DISEASE;

CENTRAL NERVOUS SYSTEM DISEASES; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MENTAL DISORDERS; SJOGREN'S SYNDROME; YOUNG ADULT;

EID: 54949112136     PISSN: 0889857X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rdc.2008.08.001     Document Type: Review

References (154)

1. Helmick C.G., Felson D.T., Lawrence R.C., et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Arthritis Rheum 58 (2008) 15-25
2. Carsons S. Sjögren's syndrome. In: Harris E.D., Budd R.C., Genovese M.C., et al. (Eds). Kelly's textbook of rheumatology (2005), Elsevier Saunders, Philadelphia 1105
3. Dafni U.G., Tzioufas A.G., Staikos P., et al. Prevalence of Sjögren's syndrome in a closed rural community. Ann Rheum Dis 56 (1997) 521-525
4. Delalande S., de Seze J., Fauchais A.L., et al. Neurologic manifestations in primary Sjögren's syndrome: a study of 82 patients. Medicine (Baltimore) 83 5 (2004) 280-291
5. Lafitte C., Amoura Z., Cacoub P., et al. Neurological complications of primary Sjögren's syndrome. J Neurol 248 (2001) 577-584
6. Font J., Ramos-Casals M., de la Red G., et al. Pure sensory neuropathy in primary Sjögren's syndrome. Long-term prospective follow-up and review of the literature. J Rheumatol 30 7 (2003) 1552-1557
7. Mellgren S.I., Conn D.L., Stevens J.C., et al. Peripheral neuropathy in primary Sjögren's syndrome. Neurology 39 3 (1989) 390-394
8. Denislic M., and Meh D. Early asymmetric neuropathy in primary Sjögren's syndrome. J Neurol 244 6 (1997) 383-387
9. Govoni M., Bajocchi G., Rizzo N., et al. Neurological involvement in primary Sjögren's syndrome: clinical and instrumental evaluation in a cohort of Italian patients. Clin Rheumatol 18 (1999) 299-303
10. Ramos-Casals M., Anaya J.M., Garcia-Carrasco M., et al. Cutaneous vasculitis in primary Sjögren's syndrome: classification and clinical significance of 52 patients. Medicine (Baltimore) 83 2 (2004) 96-106
11. Szanto A., Szodoray P., Kiss E., et al. Clinical, serologic, and genetic profiles of patients with associated Sjögren's syndrome and systemic lupus erythematosus. Hum Immunol 67 (2006) 924-930
12. Vitali C., Bombardieri S., Jonsson R., et al. Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European consensus group. Ann Rheum Dis 61 (2002) 544-548
13. Belenguer R., Ramos-Casals M., Brito-Zeron P., et al. Influence of clinical and immunological parameters on the health-related quality of life of patients with primary Sjögren's syndrome. Clin Exp Rheumatol 23 (2005) 351-356
14. Kabasakal Y., Kitapcioglu G., Turk T., et al. The prevalence of Sjögren's syndrome in adult women. Scand J Rheumatol 35 (2006) 379-383
15. Kassan S.S., Haralampos M., and Moutsopoulos H.M. Clinical manifestations and early diagnosis of Sjögren's syndrome. Arch Intern Med 164 (2004) 1275-1284
16. Manganelli P., Fietta P., and Quaini F. Hematologic manifestations of primary Sjögren's syndrome. Clin Exp Rheumatol 24 (2006) 438-448
17. Gudbjornsson B., Broman J.E., Hetta J., et al. Sleep disturbances in patients with primary Sjögren's syndrome. Br J Rheumatol 32 (1993) 1072-1076
18. Barendregt P.J., Visser M., Smets E., et al. Fatigue in primary Sjögren's syndrome. Ann Rheum Dis 57 (1998) 291-295
19. Tensing E., Solovieva S.A., Tervahartiala T., et al. Fatigue and health profile in sicca syndrome of Sjögren's and non-Sjögren's syndrome origin. Clin Exp Rheumatology 19 (2001) 313-316
20. Mauch E., Volk C., Kratzsch G., et al. Neurological and neuropsychiatric dysfunction in primary Sjögren's syndrome. Acta Neurol Scand 89 1 (1994) 31-35
21. Spezialetti R., Bluestein H.G., Peter J.B., et al. Neuropsychiatric disease in Sjögren's syndrome: anti-ribosomal P and anti-neuronal antibodies. Am J Med 95 2 (1993) 153-160
22. Malinow K.L., Molina R., Gordon O.A., et al. Neuropsychiatric dysfunction in primary Sjögren's syndrome. Ann Intern Med 103 (1985) 344-350
23. Tishler M., Barak Y., Paran D., et al. Sleep disturbances, fibromyalgia and primary Sjögren's syndrome. Clin Exp Rheumatol 15 (1997) 71-74
24. Valtysdottir S.T., Gudbjornsson B., Lindqvist U., et al. Anxiety and depression in patients with primary Sjögren's syndrome. J Rheumatol 27 (2000) 165-169
25. Valtysdottir S.T., Gudbjornsson B., Hallgren R., et al. Psycholgical well-being in patients with primary Sjögren's syndrome. Clin Exp Rheumatol 18 (2000) 597-600
26. Champey J., Corruble E., Gottenberg J.E., et al. Quality of life and psychological status in patients with primary Sjögren's syndrome and sicca symptoms without autoimmune features. Arthritis Rheum 55 (2006) 451-457
27. Escudero D., Latorre P., Codina M., et al. Central nervous system disease in Sjögren's syndrome. Ann Med Interne (Paris) 146 (1995) 239-242
28. Belin C., Moroni N., Callat-Vigneron M., et al. Central nervous system involvement in Sjögren's syndrome: evidence from neuropsychological testing and HMPAO-SPECT. An Med Interna 150 (1999) 598-604
29. Hietaharju A., Yli-Kerttula U., Hakkinen V., et al. Nervous system manifestations in Sjögren's syndrome. Acta Neurol Scand 81 (1990) 144-152
30. Drosos A.A., Andonopoulos A.P., Lagos G., et al. Neuropsychiatric abnormalities in primary Sjögren's syndrome. Clin Exp Rheumatol 7 2 (1989) 207-209
31. Segal B., Thomas W., Rogers T., et al. Prevalence, severity and predictors of fatigue in primary Sjögren's syndrome (Abstract, Suppl). Arthritis Rheum 59 (2008) in press
32. Utset T.O., Golden M., Siberry G., et al. Depressive symptoms in patients with systemic lupus erythematoussu: association with central nervous system lupus and Sjögren's sydrome. J Rheumatol 21 (1994) 2039-2045
33. Molina R., Provost T.T., and Alexander E.L. Peripheral inflammatory vascular disease in Sjögren's syndrome. Arthritis Rheum 28 (1985) 1342-1347
34. Anaya J.M., Villa L.A., Restrepo L., et al. Central nervous system compromise in primary Sjögren's syndrome. J Clin Rheumatol 8 (2002) 189-196
35. Archer H.A., Macfarlane F., Price S., et al. Do symptoms of memory impairment correspond to cognitive impairment: a cross sectional study of a clinical cohort. Int J Geriatr Psychiatry 21 (2006) 1206-1212
36. Jonker C., Geerlings M.I., and Schmand B. Are memory complaints predictive for dementia? A review of clinical and population-based studies. Int J Geriatr Psychiatry 5 (2000) 983-991
37. Reid L.M., and MacLullich A.M. Subjective memory complaints and cognitive impairment in older people. Dement Geriatr Cogn Disord 22 (2006) 471-485
38. Coates T., Slavotinek J., Rischmueller M., et al. Cerebral white matter lesions in primary Sjögren's sydrome: a controlled study. J Rheumatol 26 (1999) 1301-1304
39. Mataro M., Escudero D., Ariza M., et al. Magnetic resonance abnormalities associated with cognitive dysfunction in primary Sjögren's Syndrome. J Neurol 250 (2003) 1070-1076
40. Caselli R.J., Schneithauer B.W., and Bowles C.A. The treatable dementia of Sjögren's sydrome. Ann Neurol (1991) 98-101
41. Moll J.W., Markusse H.M., Pijnenberg J.J., et al. Anti-neuronal antibodies in patients with neurologic complications of primary Sjögren's syndrome. Neurology 43 (1993) 2574-2581
42. Pericot I., Brieva I., Tintore M., et al. Myelopathy in seronegative Sjögren's syndrome and/or progressive multiple sclerosis. Mult Scler 9 (2003) 256-259
43. Wise C.M., and Agudelo C.A. Optic neuropathy as an inital manifestation of Sjögren's syndrome. J Rheumatol 15 (1988) 799-802
44. Rapoport P., Merle H., and Smadja D. Ischemic choroidopathy in primary Sjögren's syndrome. Acta Ophthalmol Scand 76 5 (1998) 627-628
45. Pittock S.J., Lennon V.A., de Seze J., et al. Neuromyelitis optica and non-organ specific autoimmunity. Arch Neurol 65 (2008) 78-83
46. Alexander E.L., Makinow K., Lejewski J.E., et al. Primary Sjögren's syndrome with central nervous system disease mimicking multiple sclerosis. Ann Intern Med 104 (1986) 323-330
47. Wang Y., Tsai K.Y., Fuh J.L., et al. High frequency of primary Sjögren's syndrome in Tawian presenting as relapsing-remitting multiple sclerosis. Eur Neurol 51 (2004) 21-25
48. de Seze J., Devos D., Castelnovo G., et al. The prevalence of Sjögren's syndrome in patients with primary progressive MS. Neurology 57 (2001) 1359-1363
49. Noseworthy J.H., Bass B.H., Vandervoort M.K., et al. The prevalence of primary Sjögren's syndrome in a multiple sclerosis population. Ann Neurol 25 (1989) 95-98
50. Miró J., Peña-Sagredo J.L., Berciano J., et al. Prevalence of primary Sjögren's syndrome in patients with MS. Ann Neurol 27 (1990) 582-584
51. Metz L.M., Seland T.P., and Fritzler M.J. An analysis of the frequency of Sjögren's syndrome in a population of multiple sclerosis patients. J Clin Lab Immunol 30 (1989) 121-125
52. Weinshenker B.G., Wingerchuk D.M., Nakashima I., et al. OSMS is NMO, but not MS: proven clinically and pathologically. Lancet Neurol 5 (2006) 110-111
53. Misu T., Fujihara I., Nakashima I., et al. Pure optic-spinal form of multiple sclerosis in Japan. Brain 125 (2002) 2460-2468
54. Terrier B., Lacroix C., Guillevin L., et al. Diagnostic and prognostic relevance of neuromuscular biopsy in primary Sjögren's syndrome related neuropathy. Arthritis Rheum 57 (2007) 1520-1529
55. Garcia-Carrasco M., Ramos Casals M., Rosas J., et al. Primary Sjögren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore) 81 (2002) 270-280
56. Grant I.A., Hunder G.G., Homburger H.A., et al. Peripheral neuropathy associated with sicca complex. Neurology 48 4 (1997) 855-862
57. Mori K., Iijima M., Koike H., et al. The wide spectrum of clinical manifestations in Sjögren's syndrome-associated neuropathy. Brain 128 (2005) 2518-2534
58. Andonopoulos A.P., Lagos G., Drosos A.A., et al. The spectrum of neurological involvement in Sjögren's syndrome. Br J Rheumatol 29 1 (1990) 21-23
59. Gemignani F., Marbini A., Pavesi G., et al. Peripheral neuropathy associated with primary Sjögren's syndrome. J Neurol Neurosurg Psychiatr 57 8 (1994) 983-986
60. Mochizuki H., Kamakura K., Masaki T., et al. Motor dominant neuropathy in Sjögren's syndrome: report of two cases. Intern Med 41 2 (2002) 142-146
61. Goransson L.G., Herigstad A., Tjensvoll A.B., et al. Peripheral neuropathy in primary Sjögren's syndrome. Arch Neurol 63 (2006) 1612-1615
62. Griffin J.W., Cornblath D.R., Alexander E., et al. Ataxic sensory neuropathy and dorsal root ganglionitis associated with Sjögren's syndrome. Ann Neurol 27 3 (1990) 304-315
63. Malinow K., Yannakakis G.D., Glusman S.M., et al. Subacute sensory neuronopathy secondary to dorsal root ganglionitis in primary Sjögren's syndrome. Ann Neurol 20 4 (1986) 535-537
64. Segal B., Bowman S.J., Fox P.C., et al. Prevalence of sensory symptoms in primary Sjögren's syndrome (PSS) and relationship of neuropathic symptoms to depression and fibromyalgia. Arthritis Rheum 56 Suppl (2007) S448
65. Ranzenbach M., Kumar A., Rosenbaum A., et al. Anti-Ro(SS-A) autoantibodies (A-RoAb) in the immunopathogenesis of serious focal CNS disease in Sjögren's syndrome. Arthritis Rheum 35 Suppl (1992) 114
66. Alexander G.E., Provost T.T., Stevens M.B., et al. Sjögren's syndrome: central nervous system manifestations. Neurology 31 (1981) 1391-1396
67. Alexander E.L., Craft C., Dorsch C., et al. Necrotizing arthritis and spinal subarachnoid hemorrhage in Sjögren's syndrome. Ann Neurol 11 (1982) 632-635
68. Mori K., Koike H., Misu K., et al. Spinal cord magnetic resonance imaging demonstrates sensory neuronal involvement and clinical severity in neuronopathy associated with Sjögren's syndrome. J Neurol Neurosug Psychiatry 71 (2001) 488-492
69. Bakchine S., Duyckaerts C., Hassine L., et al. Central and peripheral neurologic lesions in primary Gougerot-Sjögren syndrome. Clinicopathological study of a case. Rev Neurol (Paris) 147 5 (1991) 368-375
70. Giordano M.J., Commins D., Silbergeld D.L., et al. Sjögren's cerebritis complicated by subarachnoid hemorrhage and bilateral superior cerebellar artery occlusion: case report. Surg Neurol 43 (1995) 48-51
71. Alexander E.L., Ranzenbach M.R., Kumar A.J., et al. Anti-Ro autoantibodies in central nervous system disease associated with Sjögren's syndrome: clinical, neuroimaging, and angiographic correlates. Neurology 44 5 (1994) 899-908
72. Chang C., Shiau Y., Wang J., et al. Abnormal regional cerebral blood flow on Tc ECD brain SPECT in patients with primary Sjögren's syndrome and normal findings on brain magnetic resonance imaging. Ann Rheum Dis 61 (2002) 774-778
73. Muscal E., and Brey R.L. Neurological manifestations of the antiphospholipid syndrome: risk assessments and evidence-based medicine. Int J Clin Pract 61 (2007) 1561-1568
74. Cervera R., García-Carrasco M., Font J., et al. Antiphospholipid antibodies in primary Sjögren's syndrome: prevalence and clinical significance in a series of 80 patients. Clin Exp Rheumatol 15 4 (1997) 361-365
75. Fauchais A.L., Lambert M., Launay D., et al. Antiphospholipid antibodies in primary Sjögren's syndrome: prevalence and clinical significance in a series of 74 patients. Lupus 13 (2004) 245-248
76. Tumiati B., Casoli P., and Parmeggiani A. Hearing loss in the Sjögren's syndrome. Ann Intern Med 126 (1997) 450-453
77. Alexander E.L., Arnett F., Provost TT., et al. Sjögren's syndrome: association of anti-Ro(SS-A) antibodies with vasculitis, hematolgic abnormalities, and serologic hyperreactivity. Ann Intern Med 98 (1983) 155-159
78. Simmons-O'Brien E., Chen S., Watson R., et al. One hundred anti-Ro(SSA) antibody positive patients: a 10 year follow-up. Medicine (Baltimore) 74 (1995) 109-130
79. Shusta E.V., Li J.Y., Boado R.J., et al. The Ro52/SS-A autoantigen has elevated expression at the brain microvasculature. Neuroreport 14 (2003) 1861-1865
80. Mégevand P., Chizzolini C., Chofflon M., et al. Cerebrospinal fluid anti-SSA autoantibodies in primary Sjögren's syndrome with central nervous system involvement. Eur Neurol 57 (2007) 166-171
81. Davis J.M., Moder K.G., Homburger H.A., et al. Clinical features of 39 patients with antibodies to extractable nuclear antigens despite negative antinuclear antibodies. Medicine (Baltimore) 84 (2005) 208-217
82. Eystathioy T., Chan E.K.L., Tenebaum S.A., et al. A phosphorylated cytoplasmic autoantigen, GW 182, associates with a unique population of human mRNAs within novel cytoplasmic speckles. Mol Biol Cell 13 (2002) 1338-1351
83. Bhanji R.A., Eystathioy T., Chan E.K., et al. Clinical and serological features of patients with autoantibodies to GW/P bodies. Clin Immunol 125 (2007) 247-256
84. Steinfield S., Cogan E., King L.S., et al. Abnormal distribution of aquaporin-5 water channel protein in salivary glands from Sjögren's syndrome patients. Lab Invest 81 (2001) 143-148
85. Tsubota K., Hirai S., King L.S., et al. Defective cellular trafficking of lacrimal gland AQP-5 in SS. Lancet 357 (2001) 688-689
86. Lucchinetti C.F., Mandeler R.N., Avern D., et al. A role for humeral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 125 (2002) 1450-1461
87. Lennon V.A., Wingerchuk D.M., Kryzer T.J., et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364 (2004) 2106-2112
88. Lennon V.A., Kryzer T.J., Pittock S.J., et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202 (2005) 473-477
89. Oshio K., Watanabe H., Yan D., et al. Impaired pain sensation in mice lacking aquaporin-1 water channels. Biochem Biophys Res Commun 341 4 (2006) 1022-1028
90. Tanga F.Y., Nutile-McMenemy N., DeLeo J.A., et al. The CNS role of toll-like receptor 4 in innate neuroimmunity and painful neuropathy. Proc Natl Acad Sci U S A 102 (2005) 5856-5861
91. Ledeboer A., Jekich B.M., Sloane E.M., et al. Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats. Brain Behav Immun 21 5 (2007) 686-698 [Epub 2006;21:686-98]
92. Konttinen Y.T., Tensing E., Laine M., et al. Abnormal distribution of aquaporin-5 in salivary glands in the NOD mouse model for Sjögren's syndrome. J Rheumatol 32 (2005) 1071-1075
93. Li J., Ha M., Kü N.Y., et al. Inhibitory effects of autoantibodies on the muscarinic receptors in Sjögren's syndrome. Lab Invest 84 (2004) 1430-1438
94. Hocevar A., Tomsic M., Praprotnik S., et al. Parasympathetic nervous system dysfunction in primary Sjögren's syndrome. Ann Rheum Dis 62 (2003) 702-704
95. Nagaraju K., Cox A., Casciola-Rosen L., et al. Novel fragments of the Sjögren's syndrome autoantigens alpha-fodrin and type 3 muscarinic acetylcholine receptor generated during cytotoxic lymphocyte granule-induced cell death. Arthritis Rheum 44 (2001) 2376-2386
96. Bacman S.R., Berra A., Sterin-Borda L., et al. Human primary Sjögren's syndrome autoantibodies as mediators of nitric oxide release coupled to lacrimal gland muscarinic acetylcholine receptors. Curr Eye Res 17 (1998) 1135-1142
97. Bacman S., Sterin-Borda L., Camusso J.J., et al. Circulating antibodies against rat parotid gland M3 muscarinic receptors in primary Sjögren's syndrome. Clin Exp Immunol 104 (1996) 454-459
98. Robinson C.P., Brayer J., Yamachika S., et al. Transfer of human serum IgG to nonobese diabetic Igmu null mice reveals a role for autoantibodies in the loss of secretory function of exocrine tissues in Sjögren's syndrome. Proc Natl Acad Sci U S A 95 (1998) 7538-7543
99. Bacman S., Berra A., Sterin-Borda L., et al. Muscarinic acetylcholine receptor antibodies as a new marker of dry eye Sjögren syndrome. Invest Ophthalmol Vis Sci 42 (2001) 321-327
100. Dawson L.J., Stanbury J., Venn N., et al. Antimuscarinic antibodies in primary Sjögren's syndrome reversibly inhibit the mechanism of fluid secretion by human submandibular salivary acinar cells. Arthritis Rheum 54 (2006) 1165-1173
101. Wang F., Jackson M.W., Maughan V., et al. Passive transfer of Sjögren's syndrome IgG produces the pathophysiology of overactive bladder. Arthritis Rheum 50 (2004) 3637-3645
102. Nguyen K.H., Brayer J., Cha S., et al. Evidence for antimuscarinic acetylcholine receptor antibody-mediated secretory dysfunction in nod mice. Arthritis Rheum 43 10 (2000) 2297-2306
103. Smith A.J., Jackson M.W., Wang F., et al. Neutralization of muscarinic receptor autoantibodies by intravenous immunoglobulin in Sjögren syndrome. Hum Immunol 66 (2005) 411-416
104. Waterman S.A., Gordon T.P., and Rischmueller M. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjögren's syndrome. Arthritis Rheum 43 (2000) 1647-1654
105. Dawson L.J., Allison H.E., Stanbury J., et al. Putative anti-muscarinic antibodies cannot be detected in patients with primary Sjogren's syndrome using conventional immunological approaches. Rheumatology (Oxford) 43 (2004) 1488-1495
106. Loftis J.M., Huckans M., Ruimy S., et al. Depressive symptoms in patients with chronic hepatitis C are correlated with elevated plasma levels of interleukin-1beta and tumor necrosis factor-alpha. Neurosci Lett 430 (2008) 264-268
107. Pitossi F., del Rey A., Kabiersch A., et al. Induction of cytokine transcripts in the central nervous system and pituitary following peripheral administration of endotoxin to mice. J Neurosci Res 48 (1997) 287-298
108. Konsman J.P., Parnet P., and Dantzer R. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci 25 (2002) 154-159
109. Ferrari C.C., Depino A.M., Prada F., et al. Reversible demyelination, blood-brain barrier breakdown, and pronounced neutrophil recruitment induced by chronic IL-1 expression in the brain. Am J Pathol 165 (2004) 1827-1837
110. Forster M.J., Popper M.D., Retz K.C., et al. Age differences in acquisition and retention of one-way avoidance learning in C57BL/6NNia and autoimmune mice. Behav Neural Biol 49 2 (1988) 139-151
111. Vogelweid C.M., Wright D.C., Johnson J.C., et al. Evaluation of memory, learning ability and clinical neurologic function in pathogen-free mice with systemic lupus. Arthritis Rheum 37 (1994) 889-897
112. Hess D.C., Taormina M., Thompson J., et al. Cognitive and neurologic deficits in the MRL/lpr mouse: a clinicopathologic study. J Rheumatol 20 (1993) 610-617
113. Sakic B., Szechtman H., Keffer M., et al. Neurobehavioral alteration in autoimmune mice. Neurosci Biobehav Rev 21 (1993) 327-340
114. Walker S., Wright D.C., O'Sullivan F.X., et al. Memory, learning ability, and neuropathologic status of mice with systemic lupus erythematosus. Ann NY Acad Sci 823 (1997) 107-115
115. Tomita M., Holman B.J., and Santoro T.J. Aberrant cytokine gene expression in the hippocampus in murine systemic lupus erythematosus. Neurosci Lett 302 (2001) 129-132
116. Malik U.R., Makower D.F., and Wadler S. Interferon-mediated fatigue. Cancer Pract 92 (2001) 1664-1668
117. Manns M.P., Wedemeyer H., and Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 55 (2006) 1350-1359
118. Dantzer R., Wollman E.E., and Yirmiya R. Cytokines, stress, and depression (1999), Plenum, Kluwer Academic, New York
119. Capuron L., Raison C.L., Musselman D.L., et al. Association of exaggerated HPA axis response to the initial injection of interferon-alpha with development of depression during interferon-alpha therapy. Am J Psychiatry 160 (2003) 1342-1345
120. Capuron L., and Miller A.H. Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry 56 (2004) 819-824
121. Johnson E.O., Vlachoyiannopoulos PG., Skopouli F.N., et al. Hypofunction of the stress axis in Sjögren's syndrome. J Rheumatol 35 (1998) 1508-1514
122. Kamata M., Higuchi H., Yoshimoto M., et al. Effect of single intracerebroventricular injection of alpha-interferon on monoamine concentrations in the rat brain. Eur Neuropsychopharmacol 10 (2000) 129-132
123. Capuron L., Neurauter G., Musselman D.L., et al. Interferon-alpha-induced changes in tryptophan metabolism: relationship to depression and paroxetine treatment. Biol Psychiatry 54 (2003) 906-914
124. Shiozawa S., Kuroki Y., Kim M., et al. Interferon-alpha in lupus psychosis. Arthritis Rheum 35 4 (1992) 417-422
125. Baechler E.C. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci 100 (2003) 2610-2615
126. Grandits M., Machado D.B., Meyer C.M., et al. Identification of differential gene expression patterns in Sjögren's syndrome patients. American College of Rheumatology Annual Scientific Meeting. Arthritis Rheum 46 (2002) S598
127. Emamian E.S., Leon J., Rao S., et al. Over-expression of interferon-inducible genes is highly correlated with sicca manifestations and autoantibody levels in Sjögren's syndrome. Arthritis Rheum 50 (2004)
128. Joachim R.A., Kuhlmei A., Dinh Q.T., et al. Neuronal plasticity of the "brain-skin connection": stress-triggered up-regulation of neuropeptides in dorsal root ganglia and skin via nerve growth factor-dependent pathways. J Mol Med 85 (2007) 1369-1378
129. Batbayar B., Nagy G., Kovesi G., et al. Morphological basis of sensory neuropathy and neuroimmunomodulation in minor salivary glands of patients with Sjögren's syndrome. Arch Oral Biol 49 7 (2004) 529-538
130. Soliotis F.C., Mavragani C.P., and Moutsopoulos H.M. Central nervous system involvement in Sjögren's syndrome. Ann Rheum Dis 63 (2004) 616-620
131. Alexander E.L. Neurologic disease in Sjögren's syndrome: mononuclear inflammatory vasculopathy affecting central/peripheral nervous system and muscle. Rheum Dis Clin North Am 19 (1993) 869-905
132. Dyck P.J., Oviatt K.F., and Lambert E.H. Intensive evaluation of referred unclassified neuropathies yields improved diagnosis. Ann Neurol 10 (1981) 222-226
133. McLeod J.G., Tuck R.R., Pollard J.D., et al. Chronic polyneuropathy of undetermined cause. J Neuro Neurosug Psychiatry 47 (1984) 530-535
134. In: Dyck P.J., and Thomas P.K. (Eds). Peripheral neuropathy (1993), Saunders, Philadelphia
135. Greenspan J.S., Daniels T.E., Talal N., et al. The histopathology of Sjögren's syndrome in labial saliary gland biopsies. Oral Surg Oral Med Oral Pathol 37 (1974) 217-229
136. Andoh Y., Shimura S., Sawai T., et al. Morphometric analysis of secretory glands in SS. Am Rev Respir Dis 148 (1993) 1358-1362
137. Gorson K.C., and Ropper A.H. Positive salivary gland biopsy, Sjögren's syndrome, and neuropathy: clinical implications. Muscle Nerve 28 5 (2003) 553-560
138. Peyronnard J.M., Charron L., Beaudet F., et al. Vasculitic neuropathy in rheumatoid disease and Sjögren's syndrome. Neurology 32 8 (1982) 839-845
139. Chai J., Herrmann DN., Stanton M., et al. Painful small-fiber neuropathy in Sjögren's syndrome. Neurology 65 (2005) 925-927
140. Mendell J.R., and Sahenk Z. Painful sensory neuropathy. N Engl J Med 27 (2003) 1243-1255
141. Dworkin R.H., O'Connor A.B., Backonja M., et al. Pharmacologic management of neuropathic pain: evidence-based recommendations. Pain 132 (2007) 237-251
142. Galer B.S., Rowbotham M.C., Von Miller K., et al. Treatment of inflammatory, neuropathic and sympathetically maintained pain in a patient with Sjögren's syndrome. Pain 50 2 (1992) 205-208
143. Yamada S., Mori K., Matsuo K., et al. Interferon alpha treatment for Sjögren's syndrome associated neuropathy. J Neurol Neurosurg Psychiatr 76 (2005) 576-578
144. Greenberg B.M., Thomas K.P., Krishnan C., et al. Idiopathic transverse myelitis: corticosteroids, plasma exchange, or cyclophosphamide. Neurology 68 (2007) 1614-1617
145. Visser L.H., Beekman R., Tijssen C.C., et al. A randomized, double-blind, placebo-controlled pilot study of IV immune globulins in combination with IV methylprednisolone in the treatment of relapses in patients with MS. Mult Scler 10 (2004) 89-91
146. Roed H.G., Langkilde A., Sellebjerg F., et al. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Neurology 64 (2005) 804-810
147. Sorensen P.S., Haas J., Sellebjerg F., et al. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology 63 11 (2004) 2028-2033
148. Williams C.S., Butler E., and Roman G.C. Treatment of myelopathy in Sjögren's syndrome with a combination of prednisone and cyclophosphamide. Arch Neurol 58 5 (2001) 815-819
149. De Seze J., Delalande S., Fauchais AL., et al. Myelopathies secondary to Sjögren's syndrome: treatment with monthly intrvenous cyclophosphamide associated with corticosteroids. J Rheumatol 33 (2006) 709-711
150. Papeix C., Vidal JS., de Seze J., et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler 13 (2007) 256-259
151. Konttinen Y.T., Kinnunen E., von Bonsdorff M., et al. Acute transverse myelopathy successfully treated with plasmapheresis and prdnisone in a patient with primary Sjögren's syndrome. Arthritis Rheum 30 (1987) 339-344
152. Cree B. Emerging monoclonal antibody therapies for multiple sclerosis. Neurologist 12 (2006) 171-178
153. Hauser S.L., Waubant E., Arnold DL., et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358 (2008) 676-688
154. Steinfeld S.D., Tant L., Burmester GR., et al. Epratuzumab (humanised anti-CD22 antibody) in primary Sjögren's syndrome: an open-label phase I/II study. Arthritis Res Ther 8 (2006) R129